Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Autor:
Christoffer Flensburg, Piers Blombery, David C.S. Huang, Huaxian Ma, Giovanna Pomilio, Sarah MacRaild, Sanam Loghavi, Rachel Thijssen, Fiona C. Brown, Ian J. Majewski, Jessica M. Salmon, Ing Soo Tiong, Hagop M. Kantarjian, Adam Ivey, Xufeng Chen, Keyur P. Patel, Ioannis Aifantis, A. Quaglieri, Shaun Fleming, Courtney D. DiNardo, Zhen Xu, Andrew W. Roberts, Marina Konopleva, Nik Cummings, Qi Zhang, Andrew H. Wei, Steve Kornblau, Chong Chyn Chua, Christina Glytsou
Publikováno v:
Blood. 135:791-803
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based com
Autor:
Brett M. Stevens, Mark D. Ewalt, Diana Abbott, Daniel A. Pollyea, Stephanie Chase, Jennifer Tobin, Molly Nakic, Chelsey Boggs, Jeffrey Schowinsky, Bradford Siegele, Steven R. Schuster, Jonathan A. Gutman, Keri Halsema, Enkhtsetseg Purev, Lindsey Lyle, Jeff Kaiser, Clayton A. Smith, Amanda Winters, Julie Rosser, Craig T. Jordan, Vishal Rana
Publikováno v:
Blood Advances. 3:2911-2919
Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our single-institution off-label experience with venetoclax/azacitidine, comparing outcomes with a cli
Autor:
Stephan Stilgenbauer, Lang Zhou, Su Young Kim, Shuo Ma, Michael Hallek, Kathryn Humphrey, Barbara Eichhorst, Brenda Chyla, Andrew W. Roberts, John C. Byrd, Steven Coutre, John F. Seymour, Thomas J. Kipps, Jalaja Potluri, Matthew S. Davids, William G. Wierda, Maria Verdugo, Jacqueline Nielsen
Publikováno v:
Blood. 134:111-122
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enro
Autor:
Maro Ohanian, Alessandra Ferrajoli, Mariela Sivina, Fong Clow, Zeev Estrov, Graciela M. Nogueras-Gonzalez, Michael J. Keating, Thomas Mathew, Ekaterina Kim, Xuelin Huang, Jeffrey L. Jorgensen, William G. Wierda, Hagop M. Kantarjian, Philip A. Thompson, Nitin Jain, Jianling Li, Tapan M. Kadia, Jan A. Burger, Michael Andreeff, Mei Cheng, Susan O'Brien
Publikováno v:
Blood. 133:1011-1019
Ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-ce
Autor:
W. Thomas Whitlow, Mollie E. Moran, Margaret Lucas, Jeffrey A. Jones, Ying Huang, Amy S. Ruppert, Nyla A. Heerema, Farrukh T. Awan, Kami J. Maddocks, Mark Reid, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, Corinne Hoffman, Gerard Lozanski
Publikováno v:
Blood. 132:1568-1572
Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab, Bruton’s tyrosine kinase inhibitor ibrutinib, and B-cell lymphoma protein 2 inhibitor venetoclax have demonstrated significant clinical activity in
Publikováno v:
Hematology. 2017:110-114
Cardiovascular (CV) health has emerged as an important consideration in patients with chronic myeloid leukemia (CML) because of improved prognosis. Indeed, the success of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has increased the focus on survivors
Autor:
Chani Field, Susan Branford, J. Graeme Hodgson, Timothy P. Hughes, Bronte A. Jamison, Victor M. Rivera, Stephanie Lustgarten, Alexandra L. Yeoman, David T Yeung, Haley Altamura, Wendy T Parker
Publikováno v:
Blood. 127:1870-1880
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (C
Autor:
Aziz Nazha, Michael Andreeff, Hagop M. Kantarjian, Jorge E. Cortes, Marina Konopleva, Sherry Pierce, Michelle A. Rudek, Naval Daver, Mark J. Levis, Tapan M. Kadia, Jan A. Burger, Sara Dellasala, Michael R. Grunwald, Gautam Borthakur, Trivikram Rajkhowa, Mona Lisa Alattar, Stefan Faderl, Mary Ann Richie, Guillermo Garcia-Manero, Farhad Ravandi
Publikováno v:
Blood. 121:4655-4662
Patients received 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ~1-month intervals. Forty-three acute myeloid leukemia (AML) patients with a median age of 6
Autor:
Motohiro Tsuzuki, Kazutaka Sunami, Tomoki Naoe, Yasushi Miyazaki, Masamitsu Yanada, Hiroyuki Fujita, Masafumi Taniwaki, Nobuhiko Emi, Yoshiko Atsuta, Akio Maeda, Akihiro Takeshita, Yukio Kobayashi, Katsumichi Fujimaki, Akira Ohwada, Shin Fujisawa, Kosuke Tsuboi, Shigeki Ohtake
Publikováno v:
Blood. 121:3095-3102
The optimal treatments for relapsed acute promyelocytic leukemia (APL) remain equivocal. We conducted a phase 2 study to evaluate the efficacy and feasibility of a sequential treatment consisting of induction and consolidation with arsenic trioxide (
Autor:
Christa Ho, Alice M.S. Cheung, Howard C.H. Chow, Heron H C Han, Connie J. Eaves, William W.L. Choi, Tsz Kan Fung, Si Lok, Alvin C.H. Ma, Anskar Y.H. Leung, Yok-Lam Kwong, Cheuk Him Man
Publikováno v:
Blood. 119:5133-5143
Internal tandem duplication (ITD) of the fms-related tyrosine kinase-3 (FLT3) gene occurs in 30% of acute myeloid leukemias (AMLs) and confers a poor prognosis. Thirteen relapsed or chemo-refractory FLT3-ITD+ AML patients were treated with sorafenib